# Special Issue

# Personalized Therapy and Clinical Outcomes for Chronic Pain

# Message from the Guest Editor

Chronic pain (CP) is a substantial healthcare challenge with prevalence rates between 11% and 40% and considerable economic costs. Recently, the International Association for the Study of Pain has proposed that three subtypes of CP may be differentiated based on unique causal mechanisms: 1. nociceptive, which is associated with an ongoing input from real or threatened tissue injury; 2. neuropathic, caused by injury or disease affecting the peripheral or central nervous system; 3. nociplastic, which is a new descriptor of CP and includes conditions that arise from altered nociception despite no clear evidence of actual or threatened tissue damage. Pain is a dynamic consequence of a host of biological, psychological, and social factors; hence, guidelines have recommended interdisciplinary treatment, which ideally makes use of a personalized approach. The new era of personalized medicine calls to the importance of tailoring medical and psychological interventions on individual patient characteristics. The Special Issue will aim to collect contributions on personalized therapy and clinical outcomes for any kind of CP.

## **Guest Editor**

Dr. Federica Galli

Department of Dynamic and Clinical Psychology, and Health Studies, Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy

## Deadline for manuscript submissions

closed (20 January 2024)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/145676

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm







# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

# Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

#### Editor-in-Chief

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

